Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01279083 · ClinicalTrials.gov registry record · Phase 1

Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension

A Phase 1 study, sponsored by Santen.

Completed
Registry status
Phase 1
Development phase
147
Enrollment target

NCT01279083: Completed Phase 1 study, sponsored by Santen.

NCT01279083 is a Phase 1 study that has completed, run by Santen. The registered enrollment target is 147 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (145% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01279083, a Phase 1 study, has completed, sponsored by Santen.

COMPLETED
Registry status
Phase 1
Development phase
147 participants
Enrollment target

Study Summary

To investigate the safety and efficacy of DE-112 in lowering intraocular pressure in subjects with primary open-angle glaucoma or ocular hypertension.

Primary Outcome

Change from baseline in mean diurnal IOP

Interventions

  • DRUG DE-112
  • DRUG DE-112 Vehicle Solution

Trial Details

FieldValue
Enrollment Target 147 participants
Start Date 2011-01
Est. Completion 2012-02
Phase Phase 1
Santen

32 total trials

What the finished NCT01279083 record still lists

NCT01279083 is an interventional study that assigns participants to a tested intervention. The registered 147 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (145% higher).

The record links to 0 conditions, and to 2 interventions - of which DE-112 is the first listed.

NCT01279083 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01279083 about?

NCT01279083 is a clinical study titled "Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension". To investigate the safety and efficacy of DE-112 in lowering intraocular pressure in subjects with primary open-angle glaucoma or ocular hypertension.

What is the current status of trial NCT01279083?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 147 participants. The study started on 2011-01. Estimated completion is 2012-02.

What interventions are being tested in trial NCT01279083?

The interventions under investigation include: DE-112 (DRUG), DE-112 Vehicle Solution (DRUG).

Who is sponsoring clinical trial NCT01279083?

This trial is sponsored by Santen, which has 32 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01279083's enrollment target sits among peer trials

147 387th of 2000 higher than 1,610 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04396613 · 147 participants · NA

    Wound Closure Techniques in Primary Spine Surgery

  • NCT04851119 · 147 participants · Phase 1

    Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • NCT05523947 · 147 participants · Phase 1

    Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

  • NCT06121843 · 147 participants · Phase 1

    A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01279083, the US trial registry maintained by the National Library of Medicine. NCT01279083 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.